Drug establishmentActive, Registered FY2026FDA warning letter on file

Chengdu Brilliant Biopharmaceutical Co., Ltd.

Chengdu Brilliant Biopharmaceutical Co., Ltd. is an FDA-registered drug establishment (FEI 3015530591) located in . The facility is active, registered for FY2026. FDA has issued 1 warning letter(s) to this facility.

FDA warning letter

Sep 11, 2025
CGMP/Finished Pharmaceuticals/Adulterated

A warning letter is FDA's formal notice of significant violations that require prompt correction. It can hold up product approvals, trigger import alerts, and put supply agreements at risk until the issues are resolved and FDA closes it out.

Establishment record

FEI Number
3015530591
Address
No. 33, ,
Establishment type
Drug establishment
Products / operations
ANALYSIS; API MANUFACTURE; LABEL; MANUFACTURE; PACK
Registration status
Active, Registered FY2026

Verify this record on FDA.gov ›

Inspection history

Inspections on file
None on file
Form 483 observations
None on file

FDA publishes only a subset of inspection records and Form 483s, so "None on file" is not a guarantee of a clean inspection history.

Questions

Is Chengdu Brilliant Biopharmaceutical Co., Ltd. registered with the FDA?

Yes. Chengdu Brilliant Biopharmaceutical Co., Ltd. is an FDA-registered drug establishment (FEI 3015530591) in . Its current registration status is Active, Registered FY2026.

Has Chengdu Brilliant Biopharmaceutical Co., Ltd. received an FDA warning letter?

Yes. FDA issued a warning letter to Chengdu Brilliant Biopharmaceutical Co., Ltd.; the most recent is dated Sep 11, 2025 (CGMP/Finished Pharmaceuticals/Adulterated).

What does Chengdu Brilliant Biopharmaceutical Co., Ltd. do?

Chengdu Brilliant Biopharmaceutical Co., Ltd.'s FDA-registered operations are: ANALYSIS; API MANUFACTURE; LABEL; MANUFACTURE; PACK.

Related facilities

Source: FDA public data · status as of 2026-06-01

The Enforcement Ledger

Every new FDA drug and device warning letter and recall, summarized once a week. Free.